Patients with type 2 diabetes now have an additional treatment option following the decision by the US Food and Drug Administration to authorize Onswik. The regulatory approval allows Eli Lilly to begin distributing the medication for medical use within the United States.

The clearance enables the drug to be prescribed for the management of blood sugar levels in adults with the metabolic condition, adding to the company's existing diabetes therapy portfolio.